文献速递糖尿病

在2型糖尿病且心血管高风险人群中,标准治疗基础上加用司美格鲁肽所估计的无新发或复发主要心血管事件的生命年增益

Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.
PubMed 文献 · Diabetes Care · 2022-01-01

基于SUSTAIN 6与PIONEER 6汇总队列(N=6,480)的事后分析,将司美格鲁肽加入标准治疗的主要不良心血管事件风险比为0.76(95%CI 0.62-0.92)。采用DIAL竞争风险终身心血管风险模型估计,平均获得无心血管疾病生命年1.7年(95%CI 0.5-2.9),且获益随基线风险和启动治疗年龄而异。

要点

  • 汇总队列中加用司美格鲁肽的主要不良心血管事件风险比为0.76(95%CI 0.62-0.92)。
  • 平均获得无心血管疾病生命年1.7年(95%CI 0.5-2.9)。
  • 已确诊心血管疾病者 vs 仅有心血管危险因素者:获得无心血管疾病生命年2.0 vs 0.2。

核心结论

  • 在标准治疗基础上加用司美格鲁肽与获得无心血管疾病事件生命年相关,且获益取决于基线心血管疾病风险和启动治疗时的年龄。

研究设计与样本

  • 基于SUSTAIN 6与PIONEER 6汇总队列(N=6,480)的事后分析,使用DIAL竞争风险调整的终身心血管疾病风险模型估计个体无心血管疾病生命 expectancy。

主要发现

  • 加用司美格鲁肽的主要不良心血管事件风险比为0.76(95%CI 0.62-0.92),来自汇总队列。
  • 加用司美格鲁肽平均获得无心血管疾病生命年1.7年(95%CI 0.5-2.9)。
  • 已确诊心血管疾病者 vs 仅有心血管危险因素者:获得无心血管疾病生命年2.0 vs 0.2。
  • 获得的无心血管疾病生命年随启动治疗时的年龄变化。

关键数值与推荐

  • 主要不良心血管事件风险比0.76(95%CI 0.62-0.92)。
  • 平均获得无心血管疾病生命年1.7年(95%CI 0.5-2.9)。
  • 已确诊心血管疾病者 vs 仅有心血管危险因素者:获得无心血管疾病生命年2.0 vs 0.2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Semaglutide, a glucagon-like peptide 1 receptor agonist, reduced major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) at high risk of cardiovascular disease (CVD) in a post hoc analysis of pooled data from Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN) 6 and Peptide Innovation for Early Diabetes Treatment (PIONEER) 6. We estimated the benefit of adding semaglutide to standard of care (SoC) on life-years free of new/recurrent CVD events in people with T2D at high risk of CVD. RESEARCH DESIGN AND METHODS: The Diabetes Lifetime-perspective prediction (DIAL) competing risk-adjusted lifetime CVD risk model for people with T2D was developed previously. Baseline characteristics of the pooled cohort from SUSTAIN 6 and PIONEER 6 (POOLED cohort) (N = 6,480) were used to estimate individual life expectancy free of CVD for patients in the POOLED cohort. The hazard ratio of MACE from adding semaglutide to SoC was derived from the POOLED cohort (hazard ratio [HR] 0.76 [95% CI 0.62-0.92]) and combined with an individual's risk to estimate their CVD benefit. RESULTS: Adding semaglutide to SoC was associated with a wide distribution in life-years free of CVD gained, with a mean increase of 1.7 (95% CI 0.5-2.9) life-years. Estimated life-years free of CVD gained with semaglutide was dependent on baseline risk (life-years free of CVD gained in individuals with established CVD vs. those with cardiovascular risk factors only: 2.0 vs. 0.2) and age at treatment initiation. CONCLUSIONS: Adding semaglutide to SoC was associated with a gain in life-years free of CVD events that was dependent on baseline CVD risk and age at treatment initiation. This study helps contextualize the results of semaglutide clinical trials.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Westerink J, Matthiessen KS, Nuhoho S, et al. Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk. Diabetes Care. 2022. PMID: 35263432. doi:10.2337/dc21-1138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。